Evidence map›Paper›PMID 41416004›Full record

ArticleFrontiers in bioengineering and biotechnology2025

Updated transient gene expression protocol in Expi293F cells using PEI.

Gustaf Hederoth, Andrés de la Rosa, Ana Godec, Ximena Aguilar, Antonino Napoleone, Alex Petrovic, Nicole G Metzendorf, Greta Hultqvist

Abstract read
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Gustaf Hederoth *Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Andrés de la Rosa *Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Ana GodecDepartment of Pharmacy, Uppsala University, Uppsala, Sweden.
Ximena AguilarDepartment of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.
Antonino NapoleoneDepartment of Pharmacy, Uppsala University, Uppsala, Sweden.
Alex PetrovicDepartment of Pharmacy, Uppsala University, Uppsala, Sweden.
Nicole G MetzendorfDepartment of Pharmacy, Uppsala University, Uppsala, Sweden.
Greta HultqvistDepartment of Pharmacy, Uppsala University, Uppsala, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transient gene expression (TGE) is commonly used for the rapid production of protein-based therapeutics, including antibodies that require post-translational modifications. We previously published a protocol for efficient and cost-effective TGE of multispecific and multivalent antibodies. Here, we describe an optimized version of this protocol with key improvements in cost, workflow speed, and production capacity. First, the expensive Expi293 expression medium was replaced with BalanCD HEK293 medium, resulting in a substantial decrease in medium-related costs by approximately 90%. The addition of Pluronic F-68 was omitted, as the new medium already contains a similar surfactant. To minimize plasmid DNA usage, salmon sperm DNA was included as filler DNA during transfection, enabling a significant reduction in plasmid DNA input without compromising antibody yield. Second, the harvesting procedure was shortened from 2.5 h to just 15 min by adding the mineral compound diatomaceous earth (Celpure®) to the culture supernatant. This effectively absorbs and sequesters cells and debris, allowing rapid filtration without filter clogging or the previously required 1-h centrifugation step. Finally, we recommend high-flow rate HiScreen Fibro PrismA columns to further accelerate downstream antibody purification. Together, these improvements streamline the TGE workflow in Expi293F cells, enhance scalability, and increase throughput while maintaining efficiency in antibody production.

Indexed as

celpureExpi293Flab-scalePEIprotocol updatesalmon sperm DNAtransfectiontransient gene expression protocol

Identifiers

PMID41416004
PMCPMC12709276

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.